JEMPERLI® (Dostarlimab-gxly)

The FDA on July 31, 2023, approved JEMPERLI®  with Carboplatin and Paclitaxel, followed by single-agent JEMPERLI®, for primary advanced or recurrent Endometrial Cancer (EC) that is MisMatch Repair deficient (dMMR), as determined by an FDA-approved test, or MicroSatellite Instability-High (MSI-H). JEMPERLI® is a product of GlaxoSmithKline.